NCT04644237 · OUTCOME

The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) · Source last updated 2025-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

Analysis population: Safety Analysis Set

Groups in this outcome

Trastuzumab Deruxtecan 5.4 mg/kg

Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).

Trastuzumab Deruxtecan 6.4 mg/kg

Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Trastuzumab Deruxtecan 5.4 mg/kg	102
Trastuzumab Deruxtecan 6.4 mg/kg	50

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Trastuzumab Deruxtecan 5.4 mg/kg	101	Not reported	Not reported	Not reported	Not reported
Trastuzumab Deruxtecan 6.4 mg/kg	50	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
101
group Id
OG001
value
50

denoms

counts
group Id
OG000
value
102
group Id
OG001
value
50
units
Participants

groups

description
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
id
OG000
title
Trastuzumab Deruxtecan 5.4 mg/kg
description
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
id
OG001
title
Trastuzumab Deruxtecan 6.4 mg/kg

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Analysis Set

reporting Status

POSTED

time Frame

9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

title

The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice